{"protocolSection":{"identificationModule":{"nctId":"NCT03081689","orgStudyIdInfo":{"id":"GECP 16/03_NADIM"},"organization":{"fullName":"Spanish Lung Cancer Group","class":"OTHER"},"briefTitle":"Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients","officialTitle":"Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study"},"statusModule":{"statusVerifiedDate":"2024-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-04-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-09-15","type":"ACTUAL"},"completionDateStruct":{"date":"2023-10-18","type":"ACTUAL"},"studyFirstSubmitDate":"2017-03-10","studyFirstSubmitQcDate":"2017-03-10","studyFirstPostDateStruct":{"date":"2017-03-16","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-10-08","resultsFirstSubmitQcDate":"2024-11-26","resultsFirstPostDateStruct":{"date":"2024-12-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-11-26","lastUpdatePostDateStruct":{"date":"2024-12-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spanish Lung Cancer Group","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months.","detailedDescription":"Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months.\n\nThree cycles of neoadjuvant chemotherapy in combination with nivolumab will be administered.\n\nAfter completion of neoadjuvant therapy (3 cycles) and before surgery, a tumor assessment will be done. Patients have to leave the study if there is evidence of progression. Patients with in-stable disease or partial response may be considered for surgery.\n\nThe report imaging response vs pathological response rate will be evaluated.\n\nPatients eligible for the trial are those with a histological diagnosis or cytologically proven operable and resectable non-small-cell lung cancer. The total number of patients to be included will be 46 from 23 participating sites in Spain.\n\nAccrual period of 1.5 years or until the inclusion of the last patient necessary to achieve the sample set in the protocol of 46 patients. After that all patients will be treated for 1 year with adjuvant immunotherapy and they will be followed during 3 years after adjuvant treatment."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":46,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months","interventionNames":["Drug: Nivolumab 360 mg","Drug: Paclitaxel 200mg/m2","Drug: Carboplatin AUC 6"]}],"interventions":[{"type":"DRUG","name":"Nivolumab 360 mg","description":"Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months","armGroupLabels":["Arm 1"],"otherNames":["OPDIVO"]},{"type":"DRUG","name":"Paclitaxel 200mg/m2","description":"Paclitaxel 200mg/m2 IV Q3W","armGroupLabels":["Arm 1"],"otherNames":["Paclitaxel"]},{"type":"DRUG","name":"Carboplatin AUC 6","description":"Carboplatin AUC 6 IV Q3W","armGroupLabels":["Arm 1"],"otherNames":["Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival","description":"The progression free survival is the percentage of the patients without disease progression","timeFrame":"at 24 months from the first dose of neoadjuvant treatment"}],"secondaryOutcomes":[{"measure":"Overall Survival","description":"Percentage of patients are still alive","timeFrame":"at 3 years from the first dose of neoadjuvant treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. The subjects eligible for the study are those with histologically- or cytologically- documented NSCLC who present stage IIIA disease. Locally advanced patients who present stage IIIA by the previous version can be included if are considered potencially resectable. In case of N2 disease suspicion, pathological assessment by EBUS, mediastinoscopy or thoracotomy has to be carried out for N2 confirmation.\n2. Tumor should be considered resectable before study entry\n3. Performance Status of 0 or 1\n4. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration/inclusion i. WBC ≥ 2000/μL ii. Neutrophils ≥ 1500/μL iii. Platelets ≥ 100 x103/μL iv. Hemoglobin \\> 9.0 g/dL v. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below): a. Female CrCl = (140 - age in years) x weight in kg x 0.85\n\n1\\. 72 x serum creatinine in mg/dL\n\nb. Male CrCl = (140 - age in years) x weight in kg x 1.00\n\n1. 72 x serum creatinine in mg/dL vi. AST/ALT ≤ 3 x ULN vii. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\< 3.0 mg/dL) viii. INR/APTT within normal limits\n\n   5\\. The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters\n\n   6\\. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and nacional guidelines, including the Declaration of Helsinki prior to any trial-related intervention.\n\n   7\\. Patients aged \\> 18 years\n\n   8\\. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception.\n\n   9\\. Women must not be breastfeeding\n\n   10\\. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year.\n\n   Exclusion Criteria:\n   1. All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.\n   2. Patients with active, known or suspected autoimmune disease.\n   3. Patients with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.\n   4. Patients with a history of interstitial lung disease cannot be included if they have sympthomatic ILD (Grade 3-4)\n   5. Patients with other active malignancy requiring concurrent intervention\n   6. Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a\n   7. Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study\n   8. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody,\n   9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody)\n   10. Patients with known history of testing positive for human immunodeficiency virus (HIV)\n   11. Patients with history of allergy to study drug components excipients","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mariano Provencio, MD","affiliation":"spanish Lun Cancer Group","role":"STUDY_CHAIR"}],"locations":[{"facility":"Complejo hospitalario de la coruña","city":"A Coruña","state":"Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital Reina Sofía","city":"Córdoba","state":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hospital Insular de Gran Canaria","city":"Las Palmas de Gran Canaria","state":"Gran Canaria","zip":"35016","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Hospital Puerta de Hierro","city":"Majadahonda","state":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Clínica Universitaria de Navarra","city":"Pamplona","state":"Navarre","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Complejo Hospitalario de Vigo","city":"Vigo","state":"Pontevedra","zip":"36212","country":"Spain","geoPoint":{"lat":42.23282,"lon":-8.72264}},{"facility":"Hospital de Cruces","city":"Bilbao","state":"Vizcaya","zip":"48903","country":"Spain","geoPoint":{"lat":43.26271,"lon":-2.92528}},{"facility":"Hospital General de Alicante","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital Universitari Quirón Dexeus","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall Hebrón","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clínic de Barcelona","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de La Santa Creu I Sant Pau","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"H. Duran i Reynals-ICO","city":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"H. de la Princesa","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clínico San Carlos","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Fundación Jiménez Díaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"H. La Paz","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Son Espases","city":"Palma de Mallorca","zip":"07010","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Clinico de Salamanca","city":"Salamanca","zip":"37007","country":"Spain","geoPoint":{"lat":40.96882,"lon":-5.66388}},{"facility":"Hospital Virgen de La Macrena","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Virgen Del Rocío","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Clínico Universitario de Valencia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"H. Gen. Univ. Valencia","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital La Fe","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"references":[{"pmid":"35576508","type":"RESULT","citation":"Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo MR, Casal Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martin-Lopez J, Garcia-Garcia F, Casarrubios M, Franco F, Sanchez-Herrero E, Massuti B, Cruz-Bermudez A, Romero A. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16."},{"pmid":"32979984","type":"RESULT","citation":"Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Anton C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24."},{"pmid":"39419061","type":"DERIVED","citation":"Provencio M, Nadal E, Insa A, Garcia Campelo R, Casal J, Domine M, Massuti B, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro J, Gomez de Antonio D, Macia I, Figueroa S, Fernandez Vago L, Calvo V, Palmero R, Sierra-Rodero B, Martinez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermudez A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14."},{"pmid":"34446577","type":"DERIVED","citation":"Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804."},{"pmid":"34376534","type":"DERIVED","citation":"Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia Campelo MDR, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10."},{"pmid":"34323406","type":"DERIVED","citation":"Laza-Briviesca R, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo MDR, Huidobro G, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarin C, Garcia-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491."}],"seeAlsoLinks":[{"label":"Web page of the sponsor where users can find more information about SLCG studies","url":"http://www.gecp.org"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm 1","description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"46"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm 1","description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"46"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.1","spread":"8.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"34"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"46"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"46"}]}]}]},{"title":"ECOG Performance Status Scale","description":"ECOG Performance Status Scale: It describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability\n\nGRADES:\n\nECOG 0: Fully active. ECOG 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature ECOG 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours ECOG 3: Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours ECOG 4: Completely disabled ECOG 5: Dead","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"ECOG 0","measurements":[{"groupId":"BG000","value":"25"}]},{"title":"ECOG 1","measurements":[{"groupId":"BG000","value":"21"}]},{"title":"ECOG 2","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"ECOG 3","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"ECOG 4","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"ECOG 5","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Cigarette Smoking History","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Former smoker (≥ 1 year)","measurements":[{"groupId":"BG000","value":"25"}]},{"title":"Current smoker","measurements":[{"groupId":"BG000","value":"21"}]},{"title":"Never smoker","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Histology","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Adenocarcinoma","measurements":[{"groupId":"BG000","value":"26"}]},{"title":"Squamous","measurements":[{"groupId":"BG000","value":"16"}]},{"title":"NOS/Undifferenciated","measurements":[{"groupId":"BG000","value":"4"}]}]}]},{"title":"Tumor node, metastasis staging classification","description":"8th ed.TNM for Lung Cancer Primary tumor (T) T0 means there is no evidence of a tumor T1-T4 describe the size \\& location of the tumor on a scale of 1 to 4. A larger tumor or a tumor that has grown deeper into nearby tissue will get a higher number Distant metastasis (M) M0:Cancer has not spread to other parts of the body M1:Cancer has spread to other parts of the body Regional lymph nodes (N) N1: Metastasis in ipsilateral peribronchial or ipsilateral hilar lymph \\& intrapulmonary nodes N2:Metastasis in ipsilateral mediastinal or subcarinal lymph node N3:Metastasis in contralateral node","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"T1N2M0","measurements":[{"groupId":"BG000","value":"15"}]},{"title":"T2N1M0","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"T2N2M0","measurements":[{"groupId":"BG000","value":"6"}]},{"title":"T3N1M0","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"T3N2M0","measurements":[{"groupId":"BG000","value":"13"}]},{"title":"T4N0M0","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"T1N1M0","measurements":[{"groupId":"BG000","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"The progression free survival is the percentage of the patients without disease progression","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"at 24 months from the first dose of neoadjuvant treatment","groups":[{"id":"OG000","title":"Arm 1","description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","lowerLimit":"59.9","upperLimit":"87.7"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Percentage of patients are still alive","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"at 3 years from the first dose of neoadjuvant treatment","groups":[{"id":"OG000","title":"Arm 1","description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","lowerLimit":"74.5","upperLimit":"96.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"40 months","description":"The severity of AE will be determined using CTCAE version 4.0","eventGroups":[{"id":"EG000","title":"Arm 1","description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W","deathsNumAffected":1,"deathsNumAtRisk":46,"seriousNumAffected":3,"seriousNumAtRisk":46,"otherNumAffected":43,"otherNumAtRisk":46}],"seriousEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":46}]},{"term":"Increased lipase","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":46}]}],"otherEvents":[{"term":"Asthenia or fatigue","organSystem":"General disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":23,"numAtRisk":46}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":46}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":15,"numAtRisk":46}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":46}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":12,"numAtRisk":46}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":11,"numAtRisk":46}]},{"term":"Skin disorders (rash)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":19,"numAtRisk":46}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":46}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":46}]},{"term":"Decreased appetite or anorexia","organSystem":"General disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":9,"numAtRisk":46}]},{"term":"Constipation","organSystem":"General disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":46}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":46}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":13,"numAtRisk":46}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":46}]},{"term":"Increased aminotransferases","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":46}]},{"term":"Increased serum amylase","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":46}]},{"term":"Increased creatinine level","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":46}]},{"term":"Increased lipase","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":46}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Eva Pereira","organization":"Fundación GECP","email":"gecp@gecp.org","phone":"+34934302006"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2022-06-08","uploadDate":"2024-11-26T07:24","filename":"Prot_SAP_000.pdf","size":1226900}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}